Sort by:
Keyphrases
Sclerostin
89%
Osteogenesis Imperfecta
62%
Sclerostin Inhibitor
53%
Orally Administered
53%
Proteolysis Targeting chimera (PROTAC)
53%
Liver
53%
Dual Action
53%
Liver-specific
53%
Bone Disorders
53%
Protein Degradation
53%
Specificity Protein 1
53%
GalNAc
53%
LRP4
47%
Romosozumab
26%
Asialoglycoprotein Receptor (ASGPR)
26%
COL1A2
22%
Bone Formation
20%
Bone Anabolic Effects
20%
LRP8
20%
Osteogenic Potential
20%
Systemic Clearance
17%
Hepatocytes
17%
Aptamer
17%
Sclerostin Antibody
17%
Suppression Effect
15%
Cardiovascular Risk
13%
Macrophages
13%
MC3T3-E1 Cells
13%
N-acetylgalactosamine
8%
Binding Inhibition
8%
Hydroxyapatite Binding
8%
High Affinity
8%
Control Mechanism
8%
Cell Co-culture
8%
Aptamer-based
8%
Drug Accumulation
8%
Mouse Model
8%
Targeted Protein Degradation
8%
Co-culture System
8%
Therapeutic Efficacy
8%
Wnt Signaling
8%
Spatiotemporal Control
8%
Clinical Potential
8%
Bone Mass
8%
Lysosomal Degradation
8%
Tissue Targeting
8%
Bifunctional Molecules
8%
Bone Turnover Markers
8%
Mechanistic Evidence
8%
Wnt Signaling Pathway
8%
Percent Recovery
8%
Low-density Lipoprotein Receptor-related Protein 5 (LRP5)
6%
Clinical Trials
6%
Long Half-life
6%
Osteoporosis
6%
Inhibitory Potency
6%
Healthy Rats
6%
ApoE KO Mice
6%
Osteoblast
6%
Small Molecules
6%
Inflammatory Cytokines
6%
Dose Effect
6%
Safety Profile
6%
In Vivo Data
6%
Cardiovascular System
6%
Long-term Safety
6%
FDA-approved Drugs
6%
Blocking Peptide
6%
Mechanistic Studies
6%
Small Molecule Inhibitors
6%
Therapeutic Target
6%
Bone Anabolic Therapy
6%
Small Sample Size
6%
Inhibition Strategies
6%
Oral Bioavailability
6%
Large Sample Size
6%
Pharmacology, Toxicology and Pharmaceutical Science
Sclerostin
100%
Osteogenesis Imperfecta
61%
Ltvax
53%
Bone Disease
53%
Aptamer
23%
Romosozumab
17%
Cardiovascular Risk
8%
N Acetylgalactosamine
7%
Mouse Model
7%
Hydroxyapatite
7%
Combination Therapy
7%
Medicine and Dentistry
Sclerostin
53%
Osteogenesis Imperfecta
53%
Romosozumab
17%
Ossification
13%
Cardiovascular Risk
8%
Macrophage
8%
In Vitro
8%
Cardiovascular System
8%
MC3T3
8%